Non-ribosomal peptide synthetases (NRPSs) assemble metabolites of medicinal and commercial value. Both serine and threonine figure prominently in these processes and separately can be converted to the additional NRPS building blocks 2,3-diaminopropionate (Dap) and 2,3-diaminobutyrate (Dab). Here we bring extensive bioinformatics, and experimentation to compose a unified view of the biosynthesis of these widely distributed non-canonical amino acids that both derive by pyridoxal-mediated β-elimination of the activated -phosphorylated substrates followed by β-addition of an amine donor. By examining monobactam biosynthesis in and in species where it is silent, we show that (2,3)-Dab synthesis depends on an l-threonine kinase (DabA), a β-replacement reaction with l-aspartate (DabB) and an argininosuccinate lyase-like protein (DabC). The growing clinical importance of monobactams to both withstand Ambler Class B metallo-β-lactamases and retain their antibiotic activity make reprogrammed precursor and NRPS synthesis of modified monobactams a feasible and attractive goal.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906522PMC
http://dx.doi.org/10.1016/j.isci.2024.109202DOI Listing

Publication Analysis

Top Keywords

monobactam biosynthesis
8
operon marker
4
marker c4-alkylated
4
c4-alkylated monobactam
4
biosynthesis responsible
4
responsible -diaminobutyrate
4
-diaminobutyrate production
4
production non-ribosomal
4
non-ribosomal peptide
4
peptide synthetases
4

Similar Publications

Treatment options are limited for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates due to the production of metallo-β-lactamase (MBL). The ceftazidime-avibactam (CZA)/ aztreonam (ATM) combination represents a new therapeutic approach in MBL-positive isolates. Our study aims to determine distribution of carbapenemase genes in CRKP isolates and to investigate the in vitro synergistic effect of the CZA/ATM combination.

View Article and Find Full Text PDF

Molecular characterization of extended-spectrum β-lactamases from the Akkermansia genus.

Int J Food Microbiol

January 2025

Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of pharmacy, Chengdu University, 610106 Chengdu, China. Electronic address:

Akkermansia muciniphila, a member of the Verrucomicrobiota phylum, is recognized as a key gut microbe and has emerged as a potential next-generation probiotic. Assessment of antibiotic resistance in probiotics is a prerequisite for their application, while very few is studied in Akkermansia species. To address this, eight representative class A β-lactamases (36.

View Article and Find Full Text PDF

Background: Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed. As the frequency of Enterobacterales producing metallo-β-lactamases (MBL) and/or OXA-48-like carbapenemases is increasing in some United States (US) medical centres, effective antimicrobials to treat the infections caused by these organisms are urgently needed. Aztreonam-avibactam is under clinical development for treatment of infections caused by Gram-negative bacteria, including MBL producers.

View Article and Find Full Text PDF
Article Synopsis
  • Gram-negative MDR bacteria like Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa create significant clinical challenges due to complex infections and diagnostics, especially with MBL-producing strains.
  • While colistin is effective against these pathogens, its use is limited by resistance and potential kidney damage, making it a last-resort option.
  • Newer combinations, including aztreonam with avibactam and cefiderocol, show promising results and are favored for treating MBL-producing infections, with more research needed to refine treatment strategies.
View Article and Find Full Text PDF

High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics.

ACS Infect Dis

November 2024

Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4L8, Canada.

Article Synopsis
  • Bacterial pathogens need to bypass host immune defenses and nutrient limitations to cause infections, making the use of human serum a promising medium for discovering new antibacterial drugs.
  • A recent high-throughput screen using human serum revealed compounds that not only inhibited bacterial growth but also enhanced it, particularly synthetic siderophores that help bacteria acquire iron.
  • The most effective compound, a synthetic siderophore combined with the antibiotic aztreonam, led to the creation of MLEB-22043, a broad-spectrum antibiotic that shows improved efficacy against resistant bacteria when paired with a β-lactamase inhibitor.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!